Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M þ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimens. A positive result was indicated by area staining > 25% and þ 2 or þ 3 staining intensity. Positive epithelial staining was observed in 50% of BPH specimens and 56% of cancer specimens, while positive stromal staining was observed in 73% of BPH specimens and 30% of cancer specimens. This may reflect an active role for stromal VEGF in the pathological process of BPH.
Introduction
Prostate cancer is now recognised as a frequent cause of morbidity and mortality with 17 210 new cases registered in England and Wales in 1993 and 8570 deaths. 1 Benign prostatic hyperplasia (BPH) is a histological diagnosis that can produce lower urinary tract symptoms, which led to 1.9 million physician visits in the USA in 1991. 2 Both conditions represent a major healthcare burden and a greater understanding of their pathophysiology and natural history is required. Vascular endothelial growth factor (VEGF) is a heparin binding polypeptide growth factor. 3 Elevated expression of VEGF mRNA has been demonstrated in breast cancer, correlated with poor prognosis in colonic cancer, 4 and indicates progression and a poor prognosis in non-small cell lung carcinomas. 5 Also an increase in VEGF protein has been detected in ovarian, 6 colonic, 7 breast, 8 brain 9 and liver 10 cancer. Inhibition of VEGF protein with neutralising antibodies will decrease the rate of growth of liver metastasis from colon cancer in an animal model. 11 A greater understanding of the role of VEGF in the prostate may lead to potential therapeutic strategies for both benign and malignant disease. The aim of our study was to evaluate the level of VEGF expression with the aid of immunocytochemistry in specimens of prostate cancer and BPH.
Materials and methods

Patient population
The patients included in our study had all been referred for transrectal ultrasound and biopsy, because of an elevated prostate specific antigen (PSA) and undergone a six-sector biopsy, followed by histological examination using hematoxylin and eosin stained sections to characterise the tissue. Twenty-five patients had moderate to poorly differentiated tumours and a positive bone scan and 30 patients had no evidence of prostate cancer in their biopsy specimen but findings were consistent with BPH. Patients were selected for the study from a database of patients with known metastatic disease and benign disease. The authors wished to compare two homogenous populations.
Method
Immunocytochemistry was performed on 5 mm paraffin embedded tumour sections that were deparaffinised in xylene and rehydrated in sequential graded alcohol. After dewaxing and rehydration endogenous peroxidase was blocked using hydrogen peroxide in methanol for 10 min. Antigen retrieval was then carried out by microwaving the sections in 10 mM citrate buffer pH 6.0. Following this the sections were washed in TBS prior to incubating in a-VEGF Ab diluted 1/20 in TBS overnight at 4 C. VEGF immunostaining used a rabbit polyclonal antibody (Biogenex) which specifically reacts with VEGF isoforms 121, 165, 189 and 206. After washing briefly in TBS, the sections were incubated in biotinylated swine a-rabbit Igs (1/400) for 30 min at room temperature. This was followed by a 5 min wash in TBS and 30 min incubation at room temperature in horseradish peroxidase conjugated strepavidin biotin complex. Following a 5 min wash in TBS the coloured reaction product was developed using DAB as the chromogen and H 2 O 2 as the substrate. The sections were then dehydrated cleared and placed in synthetic a mount. Serial sections of each case were used with buffer as a negative control, and sections were compared to a known positive control of glioblastoma which is known to express high levels of VEGF. 9 VEGF staining was observed in both epithelial and stromal areas and to assess the protein expression in tissue specimens a score was attributed to each separately.
The area of staining was graded as (a) 0, no stain;
The intensity of the staining was also assessed using a scoring system 0, 1 þ , 2 þ , 3 þ . Again epithelial and stromal components were assessed. For the purposes of this study, a positive result was regarded as (positive ¼ area < 25% and þ 2, þ 3 intensity). A positive result had to reflect that an appropriate area of the specimen was stained with adequate intensity as focal areas of fibroblast activity and neuroendocrine differentiation could cause intense staining but not reflect the overall activity of the sample. Each score was made by two independent collaborators and the inter observer error was 11%.
Results
For epithelial staining, a positive score was observed in 50% of BPH specimens and 56% of cancer specimens (Figures 1 and 2 ). In contrast there was a marked difference for stromal staining with 73% of BPH specimens positive and only 30% of cancer specimens positive (Figures 1 and 2 ).
Discussion
Currently, the molecular and cellular events involved in the pathogenesis of prostate cancer and benign enlargement of the prostate are the focus for a great deal of research. Angiogenesis is a concept that was first proposed by Folkman, 12 who suggested that in order for a cancer to grow to a size of greater than 2 -3 cubic millimetres it requires new vessel formation to help with nutrition and oxygenation. It is a concept that has helped to explain the rapid growth observed in malignancy as well as the abnormal proliferation of tissue in non malignant diseases such as oxygen injured retinal disease. 13 VEGF is a potent mitogen and thought to be a key factor for angiogenesis. Increased production of VEGF can be stimulated by the activation of oncogenes such as ras, the inactivation of tumour suppressor genes such as p53 and Von Hippel Landau (VHL), the activation of protein kinase C by tumour promoters; and cellular stimulation by growth factors, cytokines and hypoxia. 14 -16 Angiogenesis results from the balance of activity between a number of different factors such as proangiogenic agents basic fibroblast growth factor, acidic fibroblast growth factor, thymidine phosphorylase, scatterfactor, midkine, Transforming growth factor b1 and b2 and interleukin 8 and antiangiogenic factors such as thrombospondin 1. 17 In order to fully classify the angiogenic phenotype of a cell the activity of all these factors would have to be assessed and that the action of VEGF although important is not the sole determinant of angiogenesis. Previous studies assessing VEGF in prostate cancer have observed high expression in cancer specimens and a low level in BPH. While focal differences of VEGF staining were noted within the epithelial cell of malignant specimens, with staining most predominant at the cellular apex, they also suggested that hyperplastic glands stained very poorly. 18 They failed to differentiate between stromal and epithelial staining. We now recognise that stromalepithelial interactions are crucial for normal growth and homeostasis within the prostate and that these interactions are thought to influence the rate of development of BPH and prostate cancer. 19 It is for this reason that we Distribution of VEGF K Walsh et al specifically studied the area and intensity of VEGF in both the epithelial and stromal tissue (Figures 1 and 2 ). Our findings did not concur with the previous authors. We found a high level of epithelial staining in all prostates examined and a marked difference between cancer and benign tissue with respect to stromal staining only. Prostate cancer arises as an abnormality within epithelial tissue and the high level of VEGF staining in this area is consistent with the hypothesis that VEGF has a role in malignant disease this has been well established by other authors. 8 -10 However, the low VEGF expression observed in the stroma of patients with prostate cancer may be analogous to the sequestration of basic fibroblastic growth factor (bfgf) from epithelium to stroma that has been described in cell line studies. This paper suggested that the concentration of a particular growth factor is not dependent purely on the cell type but also on the activity of surrounding cells and tissue and changes within a cell over time. 20 The VEGF may be produced in the epithelium in large quantities and when required move to the stroma to stimulate an increase in endothelial cell proliferation and neovascularisation that is necessary for continued growth of the malignancy, in the later stages of the disease (T4 M þ ) less new vessel formation may be required in the stroma decreasing the concentration of VEGF there. Neovascularisation has been demonstrated in prostate cancer using microvessel density, where the factor VIII antibody is used to identify endothelial cells, increasing microvessel density has been shown to correlate with increasing Gleason score and presence of metastasis and is an independent predictor of progression after radical prostatectomy for Gleason score 5 to 7 tumours. 21, 22 Giving further evidence to the role of angiogenesis in malignancy. However, Increased bfgf messenger RNA a related angiogenic peptide has been found at increased levels in benign breast tissue compared with breast carcinoma, demonstrating that malignancy is not always associated with overproduction of a given angiogenic peptide. 23 McNeal has introduced the concept of embryonic reawakening to explain the hyperplasia observed in the enlarged prostate. 24 The underlying prostatic stroma induces epithelial cell development by production of paracrine growth factors. In BPH the development of nodular hyperplasia reflects the proliferation of both stroma and epithelium, but stromal hyperplasia appears to predominate thus the stromal/epithelial ratio is 2:1 in normal prostate and increases to 6:1 in BPH. 25 A number of factors have been implicated in this process and our data would seem to suggest that in BPH there is a large production of VEGF in the stroma. Increased local expression of VEGF may result from gene amplification, local upregulation or altered VEGF turnover. Further studies looking in greater detail at DNA and RNA are required to elucidate whether altered transcription or abnormal protein expression are the true cause of this variation in expression. The role of VEGF in BPH may be to cause intense stromal proliferation as opposed to epithelial proliferation which is its role in malignancy. Suggesting that the same protein may play an important but different role in the process of BPH and cancer. However, within this study we have used a relatively small number of patients so further studies with larger numbers would be required to confirm these findings, we have also compared two homogenous groups of patients one with advanced cancer and the other with benign disease. Differences between these two groups would be expected but whether these changes would be consistent across a range of patients with prostate cancer remains to be proven.
Drawing firm conclusions from studies on prostate biopsy specimens is open to bias, we are aware that a prostate biopsy may understage the Gleason grade of an overall prostate specimen 26 however, in our homogeneous group of T4 M þ prostate cancer specimens this effect would be less likely as the specimens all had advanced disease. The 5-alpha reductase inhibitor Finasteride has been shown to decrease the expression of VEGF in prostatic tissue. 26 It has also been shown that haematuria associated with BPH is reduced by the use of Finasteride, this is thought to occur by a reduction in the vascularity of the gland. 27 Its therapeutic effect on BPH has been demonstrated in a large prospective randomised control trial. 28 Perhaps the direct effect on VEGF helps contribute to this clinical result. Further work on the role of angiogenesis in BPH may result in new molecular targets for prevention and treatment of the disease.
Summary and conclusions
VEGF is a potent mitogen and is expressed in both prostate cancer and BPH, within both stromal and epithelial cells. The role of VEGF in prostate cancer has previously been established. In this study stromal staining however is greatest in BPH, perhaps reflecting an active role for VEGF in the pathological process of BPH.
